Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-
1 Month
0.00%
3 Months
0.68%
6 Months
107.63%
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AMYT---
AAPL180.960.39000.22
GOOG122.870.20000.16
MSFT326.791.53000.47
XOM107.39-0.8000-0.74
WFC42.13-0.2400-0.57
JNJ160.01-0.2500-0.16
FB---
GE106.300.23000.22
JPM141.010.28000.20
ProfitabilityValueIndustryS&P 500US Markets
47.60
10.70
36.30
-92.20
-22.42
RevenueValueIndustryS&P 500US Markets
241.60M
3.78
100.09
197.73
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.04-0.06-50.00
Q02 2022-0.04-0.0250.00
Q01 2022-0.05-0.050.00
Q04 2021-0.140.15207.14
Q03 2021-0.21-0.0766.67
Q02 2021-0.09-0.0455.56
Q01 2021--0.09-
Q03 2020--0.07-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume0
Shares Outstanding0
Shares Float0
Trades Count0
Dollar Volume0
Avg. Volume0
Avg. Weekly Volume0
Avg. Monthly Volume0
Avg. Quarterly Volume0

Amryt Pharma plc (NASDAQ: AMYT) stock closed at 14.7 per share at the end of the most recent trading day (a 0.07% change compared to the prior day closing price) with a volume of 2.38M shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 88 people. Amryt Pharma plc CEO is Joseph Amrit Wiley.

The one-year performance of Amryt Pharma plc stock is %, while year-to-date (YTD) performance is 101.37%. AMYT stock has a five-year performance of %. Its 52-week range is between and , which gives AMYT stock a 52-week price range ratio of %

Amryt Pharma plc currently has a PE ratio of 18.90, a price-to-book (PB) ratio of 1.38, a price-to-sale (PS) ratio of 3.84, a price to cashflow ratio of 4.30, a PEG ratio of 2.32, a ROA of -0.11%, a ROC of 3.01% and a ROE of -0.27%. The company’s profit margin is -22.42%, its EBITDA margin is 36.30%, and its revenue ttm is $241.60 Million , which makes it $3.78 revenue per share.

Of the last four earnings reports from Amryt Pharma plc, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Amryt Pharma plc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Amryt Pharma plc is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Amryt Pharma plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amryt Pharma plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amryt Pharma plc has a Buy technical analysis rating based on Technical Indicators (ADX : 17.39, ATR14 : 0.06, CCI20 : 264.51, Chaikin Money Flow : 0.07, MACD : 0.07, Money Flow Index : 71.36, ROC : 1.03, RSI : 69.19, STOCH (14,3) : 71.43, STOCH RSI : 1.00, UO : 59.41, Williams %R : -28.57), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amryt Pharma plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (20.00 %)
1 (16.67 %)
2 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (80.00 %)
5 (83.33 %)
4 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary Rating-
0.00
-
0.00
-
0.00

Amryt Pharma plc

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

CEO: Joseph Amrit Wiley

Telephone: +44 2030267257

Address: 196 High Road, London N22 8HH, , GB

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

58%42%

Bearish Bullish

59%41%

 

News

Stocktwits